Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXG in Stage III-IV Pancreatic Adenocarcinoma
NCT01730222Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Nov 2012
- Primary completion
- Feb 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin, paclitaxel, capecitabine and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: First cycle toxicity at 1 month, Progression-Free Survival at 6 months and 1 more. Started Nov 2012; status: completed.
02
Drugs
cisplatinpaclitaxelcapecitabinegemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01730222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730222.